Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC) · Small Cell Lung Cancer (SCLC) · Follicular Lymphoma (FL) · Sponsor: Pfizer
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment. Part 3, which is open for enrollment is seeking men who: * have Castration Resistant Prostate Cancer (CRPC) and * have previously received treatment for CRPC and have progressed from the last treatment All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort). In the assessment phase: * participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods. * participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule. * participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule. After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometosta…
This description comes directly from the study's public registry record.
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
Always discuss trial participation with your own doctor first.
| Banner-University Medical Center Tucson | Tucson, Arizona, United States | Active Not Recruiting |
| The University of Arizona Cancer Center-North Campus | Tucson, Arizona, United States | Active Not Recruiting |
| The University of Arizona Cancer Center | Tucson, Arizona, United States | Active Not Recruiting |
| Arizona Urology Specialists, PLLC | Tucson, Arizona, United States | Terminated |
| Pacific Cancer Medical Center INC | Anaheim, California, United States | Active Not Recruiting |
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte, California, United States | Active Not Recruiting |
| City of Hope Investigational Drug Services (IDS) | Duarte, California, United States | Active Not Recruiting |
| Norwalk Hospital | Norwalk, Connecticut, United States | Active Not Recruiting |
| The University of Kansas Cancer Center, Investigational Drug Services | Fairway, Kansas, United States | Active Not Recruiting |
| The University of Kansas Clinical Research Center | Fairway, Kansas, United States | Active Not Recruiting |
| The University of Kansas Hospital | Kansas City, Kansas, United States | Active Not Recruiting |
| The University of Kansas Medical Center Medical Office Building | Kansas City, Kansas, United States | Active Not Recruiting |
+ 71 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03460977